ES2103305T3 - Produccion de inhibidor de interleuquina-1 humana recombinada. - Google Patents

Produccion de inhibidor de interleuquina-1 humana recombinada.

Info

Publication number
ES2103305T3
ES2103305T3 ES91900515T ES91900515T ES2103305T3 ES 2103305 T3 ES2103305 T3 ES 2103305T3 ES 91900515 T ES91900515 T ES 91900515T ES 91900515 T ES91900515 T ES 91900515T ES 2103305 T3 ES2103305 T3 ES 2103305T3
Authority
ES
Spain
Prior art keywords
human interleukin
recombined human
inhibitor production
inhibitor
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900515T
Other languages
English (en)
Inventor
Robert Hageman
Stephen P Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Application granted granted Critical
Publication of ES2103305T3 publication Critical patent/ES2103305T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCUBRIO UN METODO PARA LA PRODUCCION DE CANTIDADES COMERCIALES DEL INHIBIDOR DE INTERLEUCINA-1 (IL-LI) ALTAMENTE PURIFICADO DESDE UN HUESPED RECOMBINANTE. TAMBIEN SE DESCUBRIO UN HUESPED E.COLI RECOMBINANTE PREFERENTE PARA UTILIZAR EN ESTE METODO.
ES91900515T 1989-11-29 1990-11-29 Produccion de inhibidor de interleuquina-1 humana recombinada. Expired - Lifetime ES2103305T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44265289A 1989-11-29 1989-11-29

Publications (1)

Publication Number Publication Date
ES2103305T3 true ES2103305T3 (es) 1997-09-16

Family

ID=23757611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900515T Expired - Lifetime ES2103305T3 (es) 1989-11-29 1990-11-29 Produccion de inhibidor de interleuquina-1 humana recombinada.

Country Status (17)

Country Link
US (1) US5453490A (es)
EP (1) EP0502956B1 (es)
JP (1) JP3014007B2 (es)
KR (1) KR0182819B1 (es)
AT (1) ATE152172T1 (es)
AU (1) AU651955B2 (es)
BR (1) BR9007883A (es)
CA (1) CA2068320C (es)
DE (1) DE69030582T2 (es)
DK (1) DK0502956T3 (es)
ES (1) ES2103305T3 (es)
FI (1) FI104733B (es)
GR (1) GR3024031T3 (es)
HK (1) HK1006856A1 (es)
HU (1) HUT64582A (es)
NO (1) NO305290B1 (es)
WO (1) WO1991008285A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) * 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN101918018B (zh) 2007-11-14 2012-12-05 再生医药有限公司 使用白介素-1受体拮抗剂作为骨髓保护剂的方法
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
EP3068438A1 (en) 2013-11-11 2016-09-21 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2220662A (en) * 1987-08-26 1990-01-17 Biogen Inc Biological materials,processes for producing biological materials and for using such materials in therapy
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
AU655766B2 (en) * 1990-05-01 1995-01-12 Chiron Corporation Interleukin-1 antagonist and uses thereof

Also Published As

Publication number Publication date
NO922138D0 (no) 1992-05-29
DE69030582T2 (de) 1998-06-25
WO1991008285A1 (en) 1991-06-13
DE69030582D1 (de) 1997-05-28
GR3024031T3 (en) 1997-10-31
ATE152172T1 (de) 1997-05-15
KR920703792A (ko) 1992-12-18
CA2068320A1 (en) 1991-05-30
FI922434L (fi) 1992-05-27
HUT64582A (en) 1994-01-28
CA2068320C (en) 2000-10-17
FI922434A0 (fi) 1992-05-27
JPH05503007A (ja) 1993-05-27
NO305290B1 (no) 1999-05-03
EP0502956A1 (en) 1992-09-16
AU651955B2 (en) 1994-08-11
US5453490A (en) 1995-09-26
EP0502956B1 (en) 1997-04-23
JP3014007B2 (ja) 2000-02-28
AU6900791A (en) 1991-06-26
DK0502956T3 (da) 1997-10-20
KR0182819B1 (en) 1999-04-01
EP0502956A4 (en) 1992-12-09
NO922138L (no) 1992-05-29
HK1006856A1 (en) 1999-03-19
FI104733B (fi) 2000-03-31
HU9201777D0 (en) 1992-12-28
BR9007883A (pt) 1992-09-29

Similar Documents

Publication Publication Date Title
ES2103305T3 (es) Produccion de inhibidor de interleuquina-1 humana recombinada.
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
ES8601108A1 (es) Procedimiento para la obtencion de eglinas b o c modificadas
ES2139024T3 (es) Produccion de xilitol por recombinacion y huesped utilizado para este procedimiento.
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
BG40815A3 (bg) Метод за получаване на пептиди
IT1242028B (it) Apparecchiatura per la produzione di sigarette.
IT8123660A0 (it) Procedimento per la produzione di un concentrato spinto di fattore viii (ahf).
IT8421885A0 (it) Procedimento per la produzione di alcoli.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
IT8123902A0 (it) Procedimento per la produzione di poliisobuteni.
BG36932A3 (bg) Метод за получаване на 1-(3-хидрокси-4-метаксибензоил)-3- хидрокси-2-пиролидинон
IT8419945A0 (it) Procedimento per la preparazione di carbapenem derivati.
DE69322029D1 (de) Methode zur Untersuchung von Wafern für das Herstellen von lichtemittierenden Elementen
ES2042726T3 (es) Beta-alquilmelatoninas.
DE68916542D1 (de) Elektrode für entladungslichtquelle.
IT1231127B (it) Procedimento per la produzione di impiallacciatura di radica artificiale mediante fogli di legno rigati.
IT1172398B (it) Procedimento per la produzione di 1,2-diclorcetano
IT8422245A0 (it) Procedimento per la preparazione di derivati del lisergolo.
ES2059444T3 (es) Procedimiento para la obtencion de acroleinas alfa,beta-substituidas.
IT1213223B (it) Procedimento di preparazionedi derivati della serie del 17 alfa-idrossi-19-nor-progesterone.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
IT8719363A0 (it) Procedimento per la produzione di calcourea.
BG36931A3 (en) Method for preparing substituted benzamide
IT1179508B (it) Procedimento per la preparazione di derivati del 2,3-diidrobenzopiranone

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502956

Country of ref document: ES